https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2025-01-29 17:15:452025-01-29 17:17:07Charles Large, Autifony CEO, talks at the 8th Sachs Neuroscience Innovation Forum in San Francisco
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2024-07-22 09:58:402024-07-22 10:00:49Charles Large, Autifony CEO, talks to BiotechTV’s Amy Brown about progress in ion channel drug discovery and exciting hopes for novel treatments for rare paediatric epilepsy disorders.
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2024-03-27 11:31:412024-03-27 11:31:41Autifony Therapeutics announces publication in Nature Communications showing how novel Kv3 modulators with therapeutic potential can bind and enhance Kv3 ion channel function
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-11-14 07:08:292023-11-14 07:08:29Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-10-04 15:13:422023-10-04 15:15:48“Autifony provides an update to the National Fragile X Foundation on our research programme in Fragile X Syndrome”
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-06-13 09:12:382023-06-13 09:12:38Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2022-10-07 12:00:412022-10-07 12:07:24Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators to address cellular dysfunction, ataxia, and seizure susceptibility in PME (Progressive Myoclonic Epilepsy, EPM7) at the American Epilepsy Society (AES) Annual Meeting, taking place 2-6 December 2022 in Nashville, Tennessee
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2022-10-03 13:05:232022-10-03 13:13:10Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia.
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Editorhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgEditor2022-03-21 09:00:262022-08-17 15:23:02Autifony to speak at the Schizophrenia International Research Society (SIRS) meeting in Florence 6 – 10th April